Comprehensive Study Notes on Heme Metabolism, Regulation, and Porphyrias

Characteristics and Functions of Heme and Hemoproteins

Heme is defined as a coordination complex consisting of a protoporphyrin IX ring with a central ferrous iron $Fe^{2+}$ atom. It serves as a vital prosthetic group, which is a tightly bound, non-polypeptide unit or cofactor required for a protein to function. Proteins that containing heme are collectively known as hemoproteins. These specialized molecules utilize the heme group to perform a diverse range of critical biological functions across various tissues.

Hemoglobin is a primary example of a hemoprotein, responsible for the vital transport of oxygen ($O_2$) and carbon dioxide ($CO_2$) throughout the circulatory system. In contrast, myoglobin functions as an oxygen storage reservoir specifically within muscle tissue. Other essential hemoproteins are involved in electron transfer and cellular respiration, most notably the cytochromes, which include cytochromes $a$, $a_3$, $b$, and $c_1$. A related group, cytochrome P450, is crucial for detoxification and synthetic pathways, playing a major role in drug metabolism and the synthesis of steroid hormones. Additionally, enzymes like catalase are tasked with the degradation of hydrogen peroxide ($H_2O_2$), a harmful reactive oxygen species, into water and oxygen. Similarly, glutathione peroxidase protects cells from oxidative damage by breaking down peroxides using reduced glutathione (GSH) as a cofactor.

The porphyrin ring itself is a large, heterocyclic organic structure that serves as the essential backbone for the heme group. It is composed of four pyrrole rings, which are five-membered rings containing nitrogen. These four rings are linked together by methine bridges (carbon atoms denoted as $-CH-$) to form a large, flat, cyclic molecule. The arrangement of the ring creates a central "pocket" designed to hold the iron atom.

The Physiological Sites and Initial Steps of Heme Synthesis

Heme synthesis occurs primarily in two locations. The first is in the erythroid precursor cells, which are immature nucleated cells in the bone marrow arising from hematopoietic stem cells. Here, heme synthesis is coupled with globin production to form hemoglobin for maturing red blood cells. The second major site is the liver, specifically within hepatocytes, where it supports the production of cytochrome P450 enzymes and other hepatic heme proteins involved in detoxification and metabolism.

The biosynthetic pathway begins in the mitochondria with the condensation of glycine and succinyl-CoA. This reaction produces $\delta$-aminolevulinic acid (ALA) and is catalyzed by the enzyme ALA synthase. This is the rate-limiting step of the entire pathway and is tightly regulated via negative feedback. Specifically, ALA synthase is allosterically inhibited by the end product, heme, to ensure that production does not exceed cellular needs. This reaction also requires pyridoxal phosphate (PLP), a derivative of Vitamin B6, as an essential cofactor. Once formed, the product $\delta$-aminolevulinic acid (ALA) exits the mitochondria and enters the cytosol for the next phase of the process.

Cytosolic Reaction Sequence and Ring Formation

In the cytosol, two molecules of ALA are condensed by the enzyme ALA dehydratase (also known as PBG synthase) to form porphobilinogen (PBG), a reaction that releases water. This specific step is highly vulnerable to environmental toxins. Lead ($Pb^{2+}$) is a potent inhibitor of ALA dehydratase, exerting its toxic effect by displacing zinc ions ($Zn^{2+}$) which are crucial for the enzyme's catalytic function.

Following the formation of PBG, four molecules of porphobilinogen are linked together by hydroxymethylbilane synthase (also called porphobilinogen deaminase or PBG deaminase) to synthesize a linear tetrapyrrole chain known as hydroxymethylbilane. This linear structure is immediately acted upon by uroporphyrinogen III synthase, which flips one of the pyrrole rings and cyclizes the structure to form the first closed ring in the pathway: uroporphyrinogen III. Subsequently, the enzyme uroporphyrinogen decarboxylase removes carboxyl groups from the four acetyl side chains, releasing four molecules of $CO_2$ and forming coproporphyrinogen III.

Final Mitochondrial Steps and the Role of Ferrochelatase

To complete the pathway, the molecule must return to the mitochondria. Here, coproporphyrinogen oxidase acts on the substrate to form protoporphyrinogen IX. A subsequent oxidation step catalyzed by protoporphyrinogen oxidase fully conjugates the ring system, creating protoporphyrin IX.

In the final and decisive step, the enzyme ferrochelatase inserts a ferrous iron atom ($Fe^{2+}$) into the center of the protoporphyrin IX ring to form functional heme. This step is also a target for lead poisoning. Lead inhibits ferrochelatase by binding to the sulfhydryl (thiol) groups at the enzyme's active site, distorting its structure and preventing catalytic function. Additionally, lead acts as a competitive inhibitor by competing with ferrous iron ($Fe^{2+}$) for insertion into the ring. This dual interference blocks the final step of synthesis, causing protoporphyrin IX to accumulate in erythrocytes.

Multilevel Regulation in the Liver

In the liver, heme governs its own production by controlling the rate-limiting enzyme, ALA synthase, at three distinct levels. The first level is genetic control via DNA transcription in the nucleus. A regulator gene produces an inactive protein called an aporepressor. When heme levels are high, heme acts as a co-repressor and binds to the aporepressor. This active complex then binds to the promoter region of the DNA, physically blocking the transcription of the ALA synthase structural gene. This "feedback repression" is a powerful but slow-acting mechanism.

The second level of control is translational. If mRNA for ALA synthase has already been transcribed, high concentrations of heme in the cytosol can directly interfere with the translation of that mRNA into protein. By binding to the mRNA itself, heme prevents ribosomes from reading the genetic code, offering a faster response than transcriptional control.

The third and most immediate level of control is post-translational and involves mitochondrial transport. Although synthesized by ribosomes in the cytosol, ALA synthase must be transported into the mitochondria to access its substrates (succinyl-CoA and glycine). Heme exerts regulation by directly inhibiting this transport machinery on the mitochondrial membrane, effectively trapping the functional enzyme in the cytosol where it cannot function.

Regulation in the Bone Marrow and Erythroid Cells

In erythroid precursor cells, the primary goal is the massive production of hemoglobin. Consequently, the regulation differs from that in the liver. First, the pathway is tightly coupled to the availability of iron. Since iron is the essential central atom for heme, its transport and uptake into the precursor cells become a rate-limiting step. If iron is scarce, heme production stalls regardless of enzyme presence.

Second, the process is governed by erythroid-specific transcription factors. These specialized proteins drive the expression of genes involved in both heme and globin synthesis. Erythropoietin (EPO), a hormone produced by the kidney, is the primary driver of red blood cell production. In the bone marrow, EPO coordinates hemoglobin synthesis by upregulating ALA synthase through the activation of transcription factors and by increasing the synthesis of transferrin receptors, which promotes the uptake of iron from transferrin.

Disorders of Heme Synthesis: Porphyrias

Porphyrias are divided into primary and secondary types. Primary porphyrias are genetic disorders caused by inherited enzyme deficiencies in the heme biosynthesis pathway, leading to the accumulation of specific intermediates. Secondary porphyrias (porphyrinurias) are acquired conditions, such as lead poisoning or iron deficiency, which result in elevated porphyrin levels.

Acute Intermittent Porphyria (AIP) is an autosomal dominant disorder caused by an inherited deficiency of hydroxymethylbilane synthase (PBG deaminase). It has an incidence of approximately $2$ per $100,000$ people. It is characterized by acute, severe attacks interspersed with long periods of remission. Clinical features are gastrointestinal and neuropsychiatric, most notably severe abdominal pain, vomiting, and constipation, along with psychosis, seizures, depression, and motor neuropathy. Notably, there is an absence of photosensitivity in AIP.

Porphyria Cutanea Tarda (PCT) is caused by a deficiency of uroporphyrinogen III decarboxylase and is also inherited as an autosomal dominant trait. It is one of the most common types of porphyria. The hallmark clinical feature is photosensitivity due to the accumulation of porphyrins in the skin. Exposure to sunlight triggers a reaction manifesting as chronic blisters, crusting, and fragility on sun-exposed areas.

Erythropoietic Protoporphyria (EPP) results from a deficiency of ferrochelatase, hindering the insertion of iron into protoporphyrin IX. It is an autosomal dominant disorder. The hallmark feature is photosensitivity that typically manifests in childhood. Unlike the blistering seen in PCT, EPP causes a painful reaction characterized by acute burning, redness, and swelling shortly after sun exposure. This occurs because protoporphyrin IX accumulates in the skin, red blood cells, and liver.

Congenital Erythropoietic Porphyria (CEP) is a rare autosomal recessive disorder caused by a deficiency of uroporphyrinogen III synthase. It presents with severe photosensitivity in infancy or childhood. Sunlight exposure causes fragile blisters that progress to secondary infections, crusting, and significant scarring. A characteristic diagnostic clue is red-colored urine due to the massive excretion of porphyrins.

Variegate Porphyria is a rare autosomal dominant disorder caused by a deficiency of protoporphyrinogen oxidase. The clinical features are diverse (or "variegated"), encompassing both the acute manifestations (abdominal pain, neuropathy, psychiatric disturbances) and cutaneous photosensitivity.

Mechanisms of Lead Poisoning in Heme Synthesis

Lead disrupts heme biosynthesis by potently inhibiting both $\delta$-aminolevulinic acid dehydratase (ALAD) and ferrochelatase. This creates a dual blockade. When ALAD is inhibited, $\delta$-aminolevulinic acid cannot be converted and accumulates in the blood and urine. ALA has neurotoxic effects that contribute to neurological symptoms such as peripheral neuropathy (including wrist drop or foot drop, where the patient cannot extend the hand or foot), confusion, seizures, ataxia, and intellectual disabilities. Because porphobilinogen is not produced, the synthesis of the porphyrin ring is halted.

Simultaneously, the inhibition of ferrochelatase on the inner mitochondrial membrane prevents the insertion of ferrous ion into the protoporphyrin IX ring. Protoporphyrin IX accumulates within the mitochondria and often binds zinc instead of iron to form zinc protoporphyrin (ZPP). ZPP serves as a key biomarker for lead poisoning in erythrocytes. The overall reduction in heme and hemoglobin synthesis results in microcytic anemia.